Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.

Clinical and translational science - 1 Jan 2021

Schulte Rachael R, Choi Leena, Utreja Nipun, Van Driest Sara L, Stein C Michael, Ho Richard H

Abstract excerpt

High-dose (HD) methotrexate (MTX) is a critical component of treatment for hematologic malignancies in children and young adults. Therapeutic drug monitoring is necessary due to substantial interindividual variation in MTX clearance. Common function-altering polymorphisms in SLCO1B1 (encodes OATP1B1, which transports MTX) may contribute to clearance variability. We performed pharmacokinetic modeling using data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Body Weight

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Lymphoid

Share to Liver-Specific Organic Anion Transporter 1

Share to Methotrexate

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Open in PubMed Open full text

Identifiers

PMID: 32961024
DOI: 10.1111/cts.12879
PMCID: PMC7877862

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.PMID 32961024Read ↗

A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial.Semantic proximity Read ↗

Genome-wide study of methotrexate clearance replicates SLCO1B1.Semantic proximity Read ↗

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.Semantic proximity Read ↗

[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].Semantic proximity Read ↗

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.Semantic proximity Read ↗

Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.Semantic proximity Read ↗

Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug TransportersSemantic proximity Read ↗

Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult non-Hodgkin lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.